German Spondyloarthritis Inception Cohort

The German Spondyloarthritis Inception cohort (GESPIC) was started 2000 as a prospective, longitudinal, multicentre, nationwide study in Germany on patients with early SpA including ankylosing spondylitis (AS, also known as radiographic axial spondyloarthritis) and non-radiographic axial SpA. The objectives of GESPIC are to learn about the course of SpA during the very early stage of the disease, to appropriately assess the outcome including radiographic progression of patients after several years of follow-up, to identify outcome predictors, to assess quality of life, function, and costs (direct and indirect costs). GESPIC has been recently expanded to recruit patients with other forms of SpA / conditions associated with SpA: acute anterior uveitis, Crohn's disease as well as with psoriasis / axial psoriatic arthritis.

NCT Number	NCT01277419
Lead Sponsor	Charite University, Berlin, Germany Collaborators: German Federal Ministry of Education and Research, AbbVie, Amgen, Centocor, Inc., Schering-Plough, Wyeth is now a wholly owned subsidiary of Pfizer, Berlin Institute of Health, Novartis, UCB Pharma
Conditions	Ankylosing Spondylitis (AS) / Radiographic Axial SpA (r-axSpA), Non-radiographic Axial Spondyloarthritis (Nr-axSpA), Axial Psoriatic Arthritis (axPsA), Acute Anterior Uveitis (AAU), Crohn Disease (CD), Ulcerative Colitis (UC)
Enrollment	1,000 participants
Start Date	2000-07
Primary Completion	2030-07 (estimated)
Study Completion	2030-07 (estimated)
Updated on ClinicalTrials.gov	2021-10-12